Comparative immunohistochemical characteristics of benign and malignant major salivary gland tumors: A retrospective study

Objectives: This study aims to characterize the cellular components of major salivary gland tumors and to identify the differentiating markers between tumor subtypes.Patients and Methods: Between January 2006 and December 2010, a total of 83 patients (42 males, 41 females; mean age 50.2±15.8 years; range, 21 to 82 years) with major salivary gland tumors (n=12 mucoepidermoid carcinomas, n=8 adenoid cystic carcinomas, n=3 acinic cell carcinomas, n=4 salivary duct carcinomas, n=2 myoepitheliomas, n=5 basal cell adenomas, n=31 pleomorphic adenomas, and n=18 Warthin tumors) with myoepithelial and epithelial immunohistochemical markers (smooth muscle actin [SMA], calponin, S100, CD10, GFAP, p63, GCDFP15, GLUT1, 34ßE12, CK14, CK19, CD117, and galectin-3) were evaluated using tissue microarray method.Results: The GFAP, S100, CK14, p63, and CK5/6 expressions were significantly lower in the malignant tumors (p

PDF

___

1. El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ. World Health Organization Classification of Head and Neck Tumours. 4th ed.Lyon: IARC Press; 2017.
2. Sternlicht MD, Barsky SH. The myoepithelial defense: a host defense against cancer. Med Hypotheses 1997;48:37-46
3. Sternlicht MD, Safarians S, Rivera SP, Barsky SH. Characterizations of the extracellular matrix and proteinase inhibitor content of human myoepithelial tumors. Lab Invest 1996;74:781-96.
4. Jones JL, Shaw JA, Pringle JH, Walker RA. Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine downregulation of MMP expression in fibroblasts and tumour cells. J Pathol 2003;201:562-72.
5. Prasad AR, Savera AT, Gown AM, Zarbo RJ. The myoepithelial immunophenotype in 135 benign and malignant salivary gland tumors other than pleomorphic adenoma. Arch Pathol Lab Med 1999;123:801-6.
6. Ianez RF, Buim ME, Coutinho-Camillo CM, Schultz R, Soares FA, Lourenço SV. Human salivary gland morphogenesis: myoepithelial cell maturation assessed by immunohistochemical markers. Histopathology 2010;57:410-7.
7. Furuse C, Sousa SO, Nunes FD, Magalhães MH, Araújo VC. Myoepithelial cell markers in salivary gland neoplasms. Int J Surg Pathol 2005;13:57-65.
8. de Araújo VC, Altemani A, Furuse C, Martins MT, de Araújo NS. Immunoprofile of reactive salivary myoepithelial cells in intraductal areas of carcinoma ex-pleomorphic adenoma. Oral Oncol 2006;42:1011-6.
9. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
10. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24.
11. Reis-Filho JS, Simpson PT, Martins A, Preto A, Gärtner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 2003;443:122-32.
12. Ogawa Y, Toyosawa S, Ishida T, Ijuhin N. Keratin14 immunoreactive cells in pleomorphic adenomasand adenoid cystic carcinomas of salivary glands. Virchows Arch 2000;437:58-68.
13. Iwafuchi H, Mori N, Takahashi T, Yatabe Y.Phenotypic composition of salivary gland tumors: an application of principal [corrected] component analysis to tissue microarray data. Mod Pathol 2004;17:803-10.
14. Nagao T, Sato E, Inoue R, Oshiro H, H Takahashi R, Nagai T, et al.Immunohistochemical analysis of salivary gland tumors: application for surgical pathology practice. Acta Histochem Cytochem 2012;45:269-82.
15. Beha G, Sarli G, Brunetti B, Sassi F, Ferrara D, Benazzi C. Morphology of the myoepithelial cell: immunohistochemical characterization from resting to motile phase. Scientific World Journal 2012;2012:252034.
16. IsicDencic T, Cvejic D, Paunovic I, Tatic S, Havelka M, Savin S. Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior. Med Oncol 2013;30:362.
17. Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 2003;94:851-7.
18. Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, et al. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 2004;3:73-81.
19. Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, et al. Human hepatocellular carcinomas with “Stemness”- related marker expression: keratin 19 expression and a poor prognosis. Hepatology 2011;54:1707-17.
20. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, et al. Changes in cytoskeletal protein composition indicative of an epithelialmesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 2005;11:8006-14.
21. Fujisue M, Nishimura R, Okumura Y, Tashima R, Nishiyama Y, Osako T, et al. Clinical Significance of CK19 Negative Breast Cancer. Cancers (Basel) 2012;5:1-11.
22. Urano M, Nagao T, Miyabe S, Ishibashi K, Higuchi K, Kuroda M. Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers. Hum Pathol 2015;46:94-103.
23. Hwang MJ, Wu PR, Chen CM, Chen CY, Chen CJ. A rare malignancy of the parotid gland in a 13-year-old Taiwanese boy: case report of a mammary analogue secretory carcinoma of the salivary gland with molecular study. Med MolMorphol 2014;47:57-61.
24. Daltoe FP, Grando LJ, Meurer MI, Rivero ER, Modolo F. A rare case of mucoepidermoid carcinoma ex pleomorphic adenoma arising in minor salivary gland: histopathological and immunohistochemical analysis. J Contemp Dent Pract 2015;16:603-6.
25. Hara K, Ito M, Takeuchi J, Iijima S, Endo T, Hidaka H. Distribution of S-100b protein in normal salivary glands and salivary gland tumors. Virchows Arch A Pathol Anat Histopathol 1983;401:237-49.
26. Jolicoeur F, Gaboury LA, Oligny LL. Basal cells of second trimester fetal breasts: immunohistochemical study of myoepithelial precursors. Pediatr Dev Pathol 2003;6:398-413.
27. Dardick I, Stratis M, Parks WR, DeNardi FG, Kahn HJ. S-100 protein antibodies do not label normal salivary gland myoepithelium. Histogenetic implications for salivary gland tumors. Am J Pathol 1991;138:619-28.
28. Gugliotta P, Sapino A, Macrí L, Skalli O, Gabbiani G, Bussolati G. Specific demonstration of myoepithelial cells by anti-alpha smooth muscle actin antibody. J Histochem Cytochem 1988;36:659-63.
29. Carmichael JD, Winder SJ, Walsh MP, Kargacin GJ. Calponin and smooth muscle regulation. Can J Physiol Pharmacol 1994;72:1415-9.
30. Bilal H, Handra-Luca A, Bertrand JC, Fouret PJ. P63 is expressed in basal and myoepithelial cells of human normal and tumor salivary gland tissues. J Histochem Cytochem 2003;51:133-9.
31. Santos GC, Carvalho KC, Falzoni R, Simoes AC, Rocha RM, Lopes A, et al. Glial fibrillary acidic protein in tumor types with cartilaginous differentiation. Mod Pathol 2009;22:1321-7.
32. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell 2009;139:871-90.
33. Kalluri R, Weinberg RA. The basics of epithelialmesenchymal transition. J Clin Invest 2009;119:1420-8.
34. Jia J, Zhang W, Liu JY, Chen G, Liu H, Zhong HY, et al. Epithelial mesenchymal transition is required for acquisition of anoikis resistance and metastatic potential in adenoid cystic carcinoma. PLoS One 2012;7:e51549.
35. Nishimura T, Furukawa M, Kawahara E, Miwa A. Differential diagnosis of pleomorphic adenoma by immunohistochemical means. J Laryngol Otol 1991;105:1057-60.
36. Epivatianos A, Poulopoulos A, Dimitrakopoulos I, Andreadis D, Nomikos A, Vlahou S, et al. Application of alpha-smooth muscle actin and c-kit in the differential diagnosis of adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Oral Oncol 2007;43:67-76.
37. Holst VA, Marshall CE, Moskaluk CA, Frierson HF Jr. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 1999;12:956-60.
38. Mino M, Pilch BZ, Faquin WC. Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma. Mod Pathol 2003;16:1224-31.
39. Andreadis D, Epivatianos A, Poulopoulos A, Nomikos A, Papazoglou G, Antoniades D, et al. Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. Oral Oncol 2006;42:57-65.
40. Salehinejad J, Mohtasham N, Bagherpour A, Abbaszadeh-Bidokhty H, Ghazi A. Evaluation of c-kit protein (CD117) expression in common salivary gland neoplasms. J Oral Maxillofac Pathol 2014;18:177-82.
41. Chandan VS, Wilbur D, Faquin WC, Khurana KK. Is c-kit (CD117) immunolocalization in cell block preparations useful in the differentiation of adenoid cystic carcinoma from pleomorphic adenoma? Cancer 2004;102:207-9.
42. Sams RN, Gnepp DR. P63 expression can be used in differential diagnosis of salivary gland acinic cell and mucoepidermoid carcinomas. Head Neck Pathol 2013;7:64-8.
43. Weiler C, Reu S, Zengel P, Kirchner T, Ihrler S. Obligate basal cell component in salivary oncocytoma facilitates distinction from acinic cell carcinoma. Pathol Res Pract 2009;205:838-42.
44. Kawahara A, Harada H, Akiba J, Kage M. Salivary duct carcinoma cytologically diagnosed distinctly from salivary gland carcinomas with squamous differentiation. Diagn Cytopathol 2008;36:485-93.
45. Teymoortash A, Pientka A, Schrader C, Tiemann M, Werner JA. Expression of galectin-3 in adenoid cystic carcinoma of the head and neck and its relationship with distant metastasis. J Cancer Res Clin Oncol 2006;132:51-6.
46. Ferrazzo KL, Alves SM Jr, Santos E, Martins MT, de Sousa SM. Galectin-3 immunoprofile in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands. Oral Oncol 2007;43:580-5.
47. Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconj J. 2002;19:543-9